Profile data is unavailable for this security.
About the company
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. It is focused in major therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
- Revenue in USD (TTM)840.00
- Net income in USD-10.27k
- Incorporated2019
- Employees68.00
- LocationSepterna Inc250 East Grand Avenue, Suite 65SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 338-3533
- Fax+1 (302) 655-5049
- Websitehttps://septerna.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp | 177.28m | -195.24m | 874.51m | 709.00 | -- | 3.91 | -- | 4.93 | -1.34 | -1.34 | 1.21 | 1.52 | 0.2778 | 4.68 | 4.92 | 250,045.10 | -30.61 | -19.69 | -35.66 | -22.06 | 58.46 | 67.18 | -110.19 | -122.27 | 3.38 | -- | 0.3725 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Rapport Therapeutics Inc | 0.00 | -63.02m | 887.34m | 58.00 | -- | 2.63 | -- | -- | -1.76 | -1.76 | 0.00 | 9.21 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Oruka Therapeutics Inc | 0.00 | -7.20m | 913.46m | 4.00 | -- | 0.9687 | -- | -- | -5.97 | -5.97 | 0.00 | 26.94 | 0.00 | -- | -- | 0.00 | -19.22 | -27.78 | -19.99 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -143.54m | 928.79m | 85.00 | -- | 1.48 | -- | -- | -2.88 | -2.88 | 0.00 | 10.80 | 0.00 | -- | -- | 0.00 | -25.35 | -12.37 | -26.45 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Prothena Corporation PLC | 217.25m | -50.92m | 933.63m | 173.00 | -- | 1.60 | -- | 4.30 | -1.01 | -1.01 | 3.94 | 10.82 | 0.318 | -- | 829.18 | 1,255,757.00 | -7.45 | -14.20 | -8.16 | -15.11 | -- | -- | -23.44 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| 89bio Inc | 0.00 | -288.96m | 960.44m | 70.00 | -- | 2.54 | -- | -- | -2.91 | -2.91 | 0.00 | 3.56 | 0.00 | -- | -- | 0.00 | -62.93 | -45.50 | -67.67 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0859 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| CARGO Therapeutics Inc | 0.00 | -147.71m | 970.42m | 116.00 | -- | 2.22 | -- | -- | -3.47 | -3.47 | 0.00 | 9.51 | 0.00 | -- | -- | 0.00 | -53.66 | -- | -59.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Nuvation Bio Inc | 2.16m | -532.28m | 986.14m | 203.00 | -- | 1.96 | -- | 456.12 | -2.17 | -2.17 | 0.009 | 1.50 | 0.0036 | -- | 0.5936 | 42,392.16 | -88.53 | -16.27 | -94.44 | -16.65 | -32.38 | -- | -24,619.84 | -- | -- | -- | 0.0165 | -- | -- | -- | 27.25 | -- | -- | -- |
| Septerna Inc | 840.00 | -10.27k | 990.43m | 68.00 | -- | -- | -- | 1,179,078.00 | -0.0003 | -0.0003 | 0.00002 | 0.0037 | -- | -- | -- | 12.35 | -- | -- | -- | -- | -- | -- | -792.86 | -- | -- | -- | 0.00 | -- | -- | -- | 102.06 | -- | -- | -- |
| Relay Therapeutics Inc | 10.01m | -345.20m | 994.25m | 294.00 | -- | 1.18 | -- | 99.37 | -2.61 | -2.61 | 0.076 | 5.03 | 0.0109 | -- | -- | 30,978.33 | -37.58 | -28.55 | -39.69 | -29.54 | -- | -- | -3,449.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Lenz Therapeutics Inc | 0.00 | -72.31m | 1.02bn | 6.00 | -- | 4.99 | -- | -- | -9.45 | -9.45 | 0.00 | 7.46 | 0.00 | -- | -- | 0.00 | -29.53 | -- | -30.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| Pharvaris NV | 0.00 | -121.20m | 1.07bn | 82.00 | -- | 3.03 | -- | -- | -2.54 | -2.54 | 0.00 | 6.55 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| Ardelyx Inc | 251.85m | -72.58m | 1.09bn | 267.00 | -- | 6.87 | -- | 4.32 | -0.3113 | -0.3113 | 1.08 | 0.6682 | 0.7664 | 3.76 | 5.22 | 943,254.70 | -22.09 | -46.14 | -26.72 | -57.32 | 85.16 | 88.15 | -28.82 | -240.87 | 3.87 | -5.94 | 0.3888 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Bicara Therapeutics Inc | 0.00 | -64.84m | 1.09bn | 32.00 | -- | -- | -- | -- | -1.25 | -1.25 | 0.00 | 3.72 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.36 | -- | -- | -- |
| MiMedx Group Inc | 342.81m | 90.79m | 1.10bn | 895.00 | 15.04 | 6.06 | 11.01 | 3.20 | 0.4961 | 0.4601 | 2.00 | 1.23 | 1.58 | 2.63 | 6.65 | 383,022.30 | 44.93 | -4.14 | 56.00 | -5.90 | 83.37 | 83.61 | 28.37 | -2.70 | 3.53 | 22.35 | 0.0951 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 28 Oct 2024 | 7.00m | 0.00% |
| BVF Partners LPas of 01 Nov 2024 | 2.45m | 0.00% |
| Invus Public Equities Advisors LLCas of 25 Oct 2024 | 1.58m | 0.00% |
| Deep Track Capital LPas of 25 Oct 2024 | 1.41m | 0.00% |
| Goldman Sachs & Co. LLC (Private Banking)as of 25 Oct 2024 | 1.41m | 0.00% |
